Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy
详细信息 查看全文
- 作者：N. T. E. Bird ; M. Elmasry ; R. Jones ; E. Psarelli ; J. Dodd ; H. Malik ; W. Greenhalf ; N. Kitteringham ; P. Ghaneh ; J. P. Neoptolemos and D. Palmer
- 刊名：British Journal of Surgery
- 出版年：2017
- 出版时间：March 2017
- 年：2017
- 卷：104
- 期：4
- 页码：328-336
- 全文大小：536K
- ISSN：1365-2168
文摘
Human equilibrative nucleoside transporters (hENTs) are transmembranous proteins that facilitate the uptake of nucleosides and nucleoside analogues, such as gemcitabine, into the cell. The abundance of hENT1 transporters in resected pancreatic ductal adenocarcinoma (PDAC) might make hENT1 a potential biomarker of response to adjuvant chemotherapy. The aim of this study was to see whether hENT1 expression, as determined by immunohistochemistry, was a suitable predictive marker for subsequent treatment with gemcitabine-based adjuvant chemotherapy.